10 September 2020 

Pfizer and BioNTech have reported positive preliminary preclinical data of their lead Covid-19 vaccine candidate, BNT162b2, in mouse and non-human primate models. In a non-human primate preclinical study, BNT162b2 was able to protect rhesus macaques against Covid-19. The vaccine candidate triggered SARS-CoV-2 neutralising antibodies in vaccinated-macaques, along with viral antigen-specific CD4+ and CD8+ T cells.

The Russian Direct Investment Fund (RDIF) has teamed up with pharmaceutical company Landsteiner Scientific to supply 32 million doses of the Russian Sputnik V vaccine to Mexico. Deliveries are set to begin in November 2020, subject to Mexican regulatory approvals.

China-based Sinovac Biotech has reported positive data from healthy adults aged 60 and above in Phase I/II clinical trials of its inactivated Covid-19 vaccine candidate, CoronaVac. According to the results, the vaccine showed good safety and immunogenicity, which was comparable to that observed in healthy adults aged 18 to 5 in the prior studies. Sinovac noted that CoronaVac appeared to be well tolerated across low dose, medium dose and high dose groups. Investigators did not report any vaccine-related serious adverse event.

Dasa has signed a letter of intent with United Biomedical subsidiary COVAXX to jointly conduct a large-scale human efficacy clinical trial of the latter’s Covid-19 vaccine candidate in Brazil. COVAXX will provide Dasa with its experimental s UB-612 vaccine for a Phase II/III clinical trial in Brazil. UB-612 is a synthetic multitope peptide-based Covid-19 vaccine candidate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.